According to "Outlook 2001," a report released by the Boston-based Tufts Center for the Study of Drug Development, the United States today spends nearly three times as much on physician services as it does for prescription drugs, and over four times as much as it does for hospital care. Although prescription drugs, as a share of total U.S. healthcare spending, increased from 5.5% a decade ago to 8.5% today, hospital expenditures declined from nearly 37% to 33% during the same time period, while spending on physician services remained nearly constant.
According to "Outlook 2001," a report released by the Boston-based Tufts Center for the Study of Drug Development, the United States today spends nearly three times as much on physician services as it does for prescription drugs, and over four times as much as it does for hospital care. Although prescription drugs, as a share of total U.S. healthcare spending, increased from 5.5% a decade ago to 8.5% today, hospital expenditures declined from nearly 37% to 33% during the same time period, while spending on physician services remained nearly constant.
"Demand in the U.S. for drugs will increase significantly over the next several decades as an aging population demands more effective medicines to treat a greater variety of chronic diseases and lifestyle conditions," said Tufts Center Director Kenneth I. Kaitin. "Shifting expenditures from hospital care to prescription medicines is one way healthcare practitioners have responded to cost pressures, and that will likely continue."
According to the report:
•Â Pharmacy benefit managers will provide more services to Medicaid and Medicare beneficiaries at the state and federal levels.
• Pharmacy benefit managers will expand their services to include a much larger disease management component.
•Â Disease management will become an integral part of the Medicare program as more disease managers participate in the Medicare Coordinated Care Demonstration.
•Â Policy makers will transfer more risk to PBMs and disease managers, leading to more integration of costs across healthcare budgets.
•Â U.S. states will increase their involvement in pharmacy assistance programs for the elderly and disabled, as well as in drug price reimbursement efforts, especially if prescription drug legislation remains stalled in Congress. PR
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.